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Colorectal cancer is frequent in Western countries. In France, with
33 400 cases per year (Benhamiche et al, 1997), it is the most
frequent cancer for both sexes and represents about 15% of all
malignant tumours (Faivre et al, 1997). Several mass-screening
trials took place in the 1980s, essentially in Anglo-Saxon coun-
tries. Haemoccult II®, the most frequently used faecal occult blood
test until now, has had its efficacy proven in three controlled trials
(Mandel et al, 1993; Hardcastle et al, 1996; Kronborg et al, 1996),
with a significant reduction of colorectal-specific mortality
between the screened groups and the control groups.
Unfortunately, the benefit obtained is low and the extension of
screening to the general population in France must overcome two
problems: the poor participation rate and the relatively low sensi-
tivity of the test. In the literature the definition of sensitivity is
variable. In fact, it is important to distinguish test sensitivity and
programme sensitivity. The latter, which is the most frequently
used, corresponds to the ability of a screening programme to detect
a cancer, and can be directly estimated with the ratio a/a + c where
‘a’ is the number of cancers detected by screening and ‘c’ the
number of cancers emerging after a negative test. The former is the
ability of a test to detect a cancer and cannot be directly estimated
since ‘c’ includes not only cancers missed by the test but also
rapidly growing cancers not yet existing at the time of the test. Its
estimation thus requires either modelling of the test reaction as a
function of the presence of occult blood in the faeces, as calculated
with the data of the Minnesota trial using a rehydrated test (Church
et al, 1997), or modelling the MST (mean sojourn time) of the
tumour as recently calculated with French data (Launoy et al,
1997). Due to this relatively low sensitivity of the test, the emer-
gence of cancer among subjects with a negative test could become
one of the problems physicians may face in mass screening. At
present, data about such cancers is sparse.
The present study describes cancers emerging after a negative
Haemoccult II® (without rehydration) from the data of the first
round of screening in the Department of Calvados, and determines
their incidence according to clinical parameters (sex, age, subsite
and stage) and the time since the test. Using this incidence, the
programme sensitivity, defined as the probability for an individual
with detectable colorectal cancer to be detected by this
programme, was estimated according to the same parameters.
POPULATION AND METHODS
Between April 1991 and the end of December 1994, a first round
of screening for colorectal cancer with Haemoccult II® was
progressively done in the six areas of the Department of Calvados
(France). The population invited for screening comprised 165 000
people aged 45–74 years. The six areas were progressively
included in the screening programme over 18 months. The tests
were first proposed by general practitioners and occupational
doctors. Letters were then sent out inviting people to obtain the
test free of charge from their general practitioner or pharmacist.
No dietary or drug restrictions were required. All tests were mailed
to a single centre and were processed without rehydration. A test
was considered positive when a blue colour appeared in the centre
or diffused from the centre to the edges of the slide within 60 s
after placing a drop of hydrogen peroxide in the centre. It was
considered borderline when the blue stain was confined to the
edges. If the result was positive or borderline, subjects were
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© 1999 Cancer Research Campaigninvited by their practitioner to undergo a colonoscopy. Screening
organization and the test modality have been described in previous
papers (Launoy et al, 1995, 1996). Of those invited for this first
round of screening, 71 307 subjects completed the test (rate parti-
cipation: 43.4%). The positivity rate was 2.8% (2020 positive
tests). Among this population, 1603 (79.4%) were fully investi-
gated (colonoscopy ± DCBE), and 1277 (63.2%) had a complete
colonoscopy. Thus 152 cancers were diagnosed and the predictive
positive value for cancer was 9.5%.
All the cancers diagnosed between 1991 and 1995 in people
living in the department were recorded by the local digestive
cancer registry, whether they occurred in a subject participating in
the screening or not. In this way, four different groups were consti-
tuted:
1. Cancers occurring after a positive test in participating indivi-
duals (positive-test group)
2. cancers occurring after a negative test in participating indivi-
duals (negative-test group)
3. cancers occurring in people refusing to participate (refusers
group)
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Table 1 Characteristics of colorectal cancer in Department of Calvados between 1991 and 1995 for people aged 45 to 74
Positive test Negative test Non-responders Reference Total
Sex
Male 94 (61.8) 52 (52.0) 207 (59.8) 207 (58.1) 560
Female 58 (36.2) 48 (48.0) 139 (40.2) 149 (41.9) 394
Stagea
I 69 (45.4) 28 (28.0) 85 (24.6) 84 (23.6) 266
II 83 (54.6) 72 (72.0) 265 (75.4) 272 (76.4) 692
Age
45–54 13 (8.5) 10 (10.0) 35 (10.1) 35 (9.8) 93
55–64 47 (31.0) 35 (35.0) 112 (32.4) 120 (33.7) 314
65–74 92 (60.5) 55 (55.0) 199 (57.5) 201 (56.5) 547
Subsite
Proximal 26 (17.1) 25 (25.0) 78 (22.5) 74 (20.8) 203
Distal 98 (64.5) 42 (42.0) 155 (44.8) 176 (49.4) 471
Rectum 26 (17.1) 33 (33.0) 110 (31.8) 106 (29.8) 275
Unknown 2 (1.3) 0 3 (0.9) 0 5
Total 152 100 346 356 954
aStage I: Dukes’ A; Stage II: all the others.
Table 2 Distribution of sex, age, stage and subsite of cancer occurring after a negative test according to the time since test
First year Second year Third year Total
Sex
Male 23 (51.1) 16 (51.6) 13 (54.2) 52
Female 22 (48.9) 15 (48.4) 11 (45.8) 48
Stagea
I 14 (31.1) 10 (32.3) 4 (16.7) 28
II 31 (68.9) 21 (67.7) 20 (83.3) 72
Age
45–54 4 (8.9) 4 (12.9) 2 (8.3) 10
55–64 17 (37.8) 10 (32.3) 8 (33.3) 35
65–74 24 (53.3) 17 (54.8) 14 (58.4) 55
Subsite
Proximal 8 (17.8) 11 (35.5) 6 (25.0) 25
Distal 24 (53.3) 9 (29.0) 9 (37.5) 42
Rectum 13 (28.9) 11 (35.5) 9 (37.5) 33
Total 45 31 24 100
aStage I: Dukes’ A; Stage II: all the others.
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Figure 1 Programme sensitivity according to time since test4. cancers occurring before the offer of screening (reference
group).
The follow-up was at least 12 months for all the negative test
group, 24 months for 90.5% and 36 months only for 38.5% of it.
These values were taken into account for the calculation of
colorectal cancer incidence after a negative test. For example,
people who completed the test in May 1994, with an 18-month
follow-up, were considered as censored data over this period for
the determination of incidence.
The programme sensitivity was estimated by Sep = a/a + c, ‘a’
being the number of cancers detected with a positive test and ‘c’ the
number of cancers occurring after a negative test. After 12 months,
cancers emerging after a negative test were known only for people
who had a long enough follow-up period. So after 12 months, ‘c’ in
the formula Sep = a/a + c was estimated by applying an incidence
calculated as above to the total number of negative tests.
Extension of cancers was classified according to two stages:
stage I (Dukes’A: carcinoma not yet extended through the muscu-
laris propria and no regional lymph node metastasis (Dukes,
1932)) and stage II for all the others. Subsite was classified
according to three segments: the proximal colon including
caecum, ascending colon, hepatic flexure and transverse colon; the
distal colon with splenic flexure, descending colon, sigmoid colon
and rectosigmoid, and the rectum.
The incidence and the programme sensitivity were calculated
with Microsoft® Excel 5.0 software and for statistical analysis,
SAS® System for Windows™, Release 6.10 software was used.
RESULTS
Cancers occurring after a negative test
From 1 January 1991 to 31 December 1995, 988 cancers were
diagnosed in Calvados: 152 (16.0%) after a positive test (positive-
test group), 100 (10.5%) after a negative test (negative-test group),
346 (36.3%) in the non-responder subjects (refusers group) and
356 (37.3%) before screening invitation (reference group). Thirty-
four cancers were excluded: 22 (2.2%) for incomplete data and 12
(1.2%) cases diagnosed more than 36 months after a negative test.
Table 1 shows the distribution of clinical characteristics of
cancer according to group. Cancers in the negative-test group were
significantly different from those of the positive-test group,
regarding stage (P < 0.05) and subsite (P < 0.05), but not from the
refusers group or the reference group.
Table 2 shows clinical characteristics (sex, age, stage, subsite)
of cancers occurring after a negative test according to the time
since test. No significant difference was found in distribution of
sex, age, stage and subsite according to the time since test.
Table 3 shows the evolution of incidence of cancer among
people with a negative test according to the clinical parameters.
Mean incidence during this period was 57.7 per 100 000. In
comparison, calculated incidence in the reference group for the
same period was 141.6 per 100 000, more than twice the mean
incidence in the negative-test group.
Programme sensitivity after first round
Figures 1 and 2 show the evolution of sensitivity of the programme
estimated as described above. Globally, programme sensitivity was
77.2% at 1 year, 66.3% at 2 years and 55.9% at 3 years.
Programme sensitivity followed the same evolution in time
(Figure 2) for men and women. One year after the test it was
respectively 80.3% and 72.5%; 70.3% and 60.7% after 2 years;
and 60.5% and 50.1% 3 years after the test. The sensitivity ratio
was quite stable with time for these 3 years (1.10, 1.15 and 1.20).
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Table 3 Incidence of colorectal cancer per 100 000 after a negative test according to time and clinical parameters
Time People at Cumulated Cumulated Cumulated incidence Cumulated incidence Cumulated
the beginning incidence incidence according to age according to subsite incidence
of the period according to according
sex to stagea
Male Female 45–54 55–64 65–74 Proximal Distal Rectal I II
0–6 69 271 31.8 (18.5–45.0) 34.3 29.9 4.1 37.2 62.9 4.3 23.1 7.2 11.5 26.0
7–12 69 249 65.0 (46.0–83.9) 78.8 54.9 16.3 70.2 125.9 11.5 36.1 18.8 21.7 49.1
13–18 69 229 86.6 (64.7–108.6) 102.8 74.9 24.4 90.9 167.9 21.7 43.3 23.1 27.4 65.0
19–24 62 702 111.4 (83.3–139.5) 135.8 93.7 33.5 113.4 217.8 27.8 49.5 35.5 37.0 80.1
25–30 42 909 133.3 (89.5–177.2) 173.9 103.5 43.8 129.6 262.0 33.8 57.6 39.4 42.7 96.3
31–36 26 648 173.1 (93.0–253.1) 210.3 144.0 43.8 172.0 353.8 42.4 73.4 54.7 45.4 133.4
aStage I: Dukes’ A; Stage II: all the others.
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Figure 2 Programme sensitivity according to sex.Programme sensitivity was constantly better for people aged
65–74 years than for the others (Figure 3): 1 year after the test, the
sensitivity was 79.3% (65–74 years) versus 73.4% (55–64 years)
and 76.5% (45–54 years); the corresponding figures after 2 years
were 68.9%, 63.1% and 61.3%, and after 3 years were 57.7%,
53.0% and 54.7%.
Figure 4 shows the evolution of programme sensitivity
according to subsite. One year after the test, sensitivity was 80.3%
for distal cancer, 77.4% for proximal cancer and 66.7% for rectal
cancer. During the following period, sensitivity for distal colon
was markedly different from the other two subsites. Two years
after, programme sensitivity was 73.3% for distal cancer, 55.4%
for proximal cancer and 51.4% for rectal cancer. Three years after,
the corresponding figures were, respectively, 64.9, 45.0 and
40.7%. The ratio between distal cancer and other subsites
increased in time: 1.15 after 1 years, 1.37 after 2 years and
1.51 after 3 years.
Programme sensitivity was better for less advanced cancer. One
year after the test, it was 81.1% for stage I and 72.2% for stage II.
The corresponding figures after 2 years were, respectively, 72.9%
and 59.9%, and after 3 years, 68.7% and 47.3% (Figure 5).
DISCUSSION
According to our results, cancers emerging after a negative test do
not differ from those of the reference and non-responder groups, in
particular for stage of extension. In the two European prospective
trials, cancers emerging after a negative test were diagnosed with a
better stage than those occurring in the control group (Hardcastle
et al, 1996; Kronborg et al, 1996). This conflict could be due to a
higher rate of Dukes’ A stage among reference or non-responder
subjects in our study (respectively 23.6% and 24.6%) than corre-
sponding rates observed among the control groups in Fünen or
Nottingham (11.0%), which revealed a difference in the health
care systems of two European countries. The use of colonoscopy
has been widespread in France since the 1980s, so access to
colonoscopy is certainly easier in France. In fact, the percentage of
stage I (Dukes’A) in our reference group is similar to that of the
control group from Minnesota, where subjects were volunteers
from a cancer society. In no study do cancers after a negative test
present a worse extension than those of the reference group.
Therefore, whatever the country, patients and physicians do not
seem to be falsely reassured by a negative Haemoccult II® and are
watchful of symptoms. In our study, the incidence in the negative-
test group was about half that of the reference group, in accor-
dance with the results of Allison showing that negative subjects
had only half the likelihood of developing colorectal cancer than
the general population (Allison et al, 1990).
From a public health point of view, programme sensitivity is of
greater importance than test sensitivity, because it reflects
programme efficacy after integrating several determinants such as
test sensitivity and natural history of cancer. The best way to esti-
mate programme sensitivity is to obtain available data from several
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Figure 3 Programme sensitivity according to age Figure 5 Programme sensitivity according to stage
Figure 4 Sensitivity of the programme according to the cancer subsiterounds of screening. In our study, we estimated programme sensi-
tivity after only one round. In this condition, our programme sensi-
tivity was globally higher than that estimated in the other European
trials. The general programme sensitivity was 77.2% 1 year after
the test, while it was 50% in the study of Allison et al, and 89.3% in
the Minnesota trial that used a rehydrated test. Two years after the
test, it was 68.5%, which is higher than the calculated sensitivity
from the Fünen (44.8–48.0%) and Nottingham (48.7–67.6%) trials.
This difference may be due to the fact that our study focused only
on the first round of screening, prevalent cancers detected with the
test being more numerous for the first round than for the others. For
example, using the data from Fünen, the sensitivity after the first
round was 80.0% (37 detected cancers and nine interval cancers),
whereas after two rounds the sensitivity fell to 55.0% (50 screen-
detected cancers and 40 interval cancers) (Kronborg et al, 1989,
1996). It could also result from the difference in the positive rate of
Haemoccult II®: 1–1.2% in Nottingham, 0.8–1.8% in Fünen, 1.4%
in the Allison study and 2.8% in the Calvados programme. This
variation of positive rates could be due to the dietary restriction 3
days before taking the test in Fünen, the repetition of testing after a
first positive test with one to four positive slides in Nottingham and
the consideration of a borderline test as positive in Calvados
(Kronborg et al, 1987; Launoy et al, 1995; Robinson et al, 1995).
Programme sensitivity was better for males and for subjects aged
65–74 years, in accordance with the results from the Minnesota and
Fünen studies. Programme sensitivity was also different according
to the subsite, and higher for the distal colon 1 year after the test,
despite a higher incidence of distal cancer among the negative-test
group in comparison with other subsites. This surface discrepancy
may have two causes. First, distal cancers are the most frequent in
the general population. For instance, between 1978 and 1990, crude
incidence in Calvados was 35.9/100 000 for distal cancer, 26.2/
100 000 for rectal cancer and 17.8/100 000 for proximal cancer
(unpublished data). Secondly, regarding the natural history of
colorectal cancer, the MST for distal cancer has been estimated to
be about twice as long as the other two subsites: 6.44 years versus
3.49 years for proximal cancer and 2.61 years for rectal cancer
(Launoy et al, 1997). It seems reasonable to think that the cancers
emerging in the first year after a negative test are mainly missed
cancers, and that the longer the time since the test, the higher the
proportion of real surfacing cancers. Thus, since test sensitivity is
similar for the various subsites (Launoy et al, 1997), programme
sensitivity during the first year after the test is also similar.
Moreover, since distal cancer grows more slowly than the others,
programme sensitivity tends to be better for this localization in
subsequent years.
The finding that cancers diagnosed after a negative Haemoccult
II® do not have a worse stage of extension than those diagnosed
among general population is an encouraging result, since it reduces
the expected negative effect due to the low sensitivity of the test.
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